LS9 appoints Tjerk de Ruiter as board chairman, Afeyan steps down
LS9 Inc. announced that the company's board of directors has appointed Tjerk de Ruiter to its board and has also elected him as its chairman, effective immediately. As a result of de Ruiter’s appointment, Noubar Afeyan will be stepping down as chairman, but will remain a member of the board.
"Tjerk is a creative, dedicated and strategic business leader with relevant and extensive operations and commercial experience, and we could not be more pleased to welcome him as our chairman of the board," said Ed Dineen, president and CEO. "His proven track record in industrial biotechnology is a great fit with the current position of LS9. We look forward to partnering with Tjerk and the rest of the Board in leading LS9 into the commercial arena for our first wave of products. As a co-founder of LS9, we are grateful for the guidance from Noubar to lead LS9 through its incubation and initial development, and we look forward to his continued involvement on the board."
De Ruiter spent 12 years at Danisco and spent his last five years with the company as the CEO of the Genencor division and a member of the Danisco executive committee. At Genencor, he refocused the business on its core competences and in the process created one of the leading global industrial biotech companies. Prior to becoming CEO of the Genencor division, de Ruiter was chief operating officer of cultures, specialties and flavors at Danisco where he was responsible for three of the high growth product areas of Danisco. Previously, de Ruiter spent 11 years with Quest International and three years with Naarden International. He received his bachelors degree in business administration from the University Nijenrode in Breukelen, Netherlands, and his masters of international management from the American Graduate School of International Management, Thunderbird.